Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a payment that becomes due if the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.